MUC1 and cancer: Although the above data demonstrated that Apt-Td could carry more doxorubicin into MUC1-positive cancer cells versus MUC1-negative control cells, it was still unknown whether Apt-Td-Dox would generate a MUC1-targeted cytotoxicity against the tumor cells.